DNA REPAIR DEFECTS DRIVE GENOMIC INSTABILITY AND TUMOR IMMUNOGENICITY
K. Mouw,Michael S. Goldberg,P. Konstantinopoulos,A. D’Andrea
Abstract:DNA-damaging agents are widely used in clinical oncology and exploit defi ciencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies. Signifi cance: Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair defi ciency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. Cancer Discov; 7(7); 675–93. ©2017 AACR. 1 Department of Radiation Oncology, Brigham & Women’s Hospital/DanaFarber Cancer Institute, Boston, Massachusetts. 2 Harvard Medical School, Boston, Massachusetts. 3 Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts. 4 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts. 5 Medical Gynecology Oncology Program, Dana-Farber Cancer Institute, Boston, Massachusetts. 6 Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts. Corresponding Author: Alan D. D’Andrea , Dana-Farber Cancer Institute, 450 Brookline Avenue, HIM 243, Boston, MA 02215 . Phone: 617-6322080; Fax: 617-632-6069; E-mail: alan_dandrea@dfci.harvard.edu doi: 10.1158/2159-8290.CD-17-0226 ©2017 American Association for Cancer Research. DNA REPAIR PATHWAY ALTERATIONS ARE CANCER DRIVERS DNA is continually exposed to endogenous and exogenous sources of damage, and the coordinated activity of multiple DNA repair pathways is required to maintain genomic integrity under normal cellular conditions ( 1, 2 ). Failure to repair DNA damage in an accurate and timely manner can result in a variety of genomic aberrations, including point mutations, chromosomal translocations, and gain or loss of chromosomal segments or entire chromosomes ( 3 ). In some cases, these genomic alterations produce changes in cell physiology that drive tumor initiation ( 4–6 ). In addition to playing a role during the earliest events in tumorigenesis, loss of DNA repair fi delity has important implications for tumor evolution and response to therapy. Common tumor features such as high levels of oxidative stress, replicative stress, and loss or suppression of DNA damage–induced cell-cycle checkpoints contribute to an environment that is rich in sources of DNA damage ( 7 ). Further exacerbating the high levels of DNA damage, functional loss of one or more DNA repair pathways is common in tumors, and recent sequencing-based and functional studies have begun to reveal the broad scope of DNA repair pathway defi ciencies across cancer ( 8, 9 ). Due to the frequent combination of increased levels of DNA damage and decreased DNA repair capacity, most cancer cells accumulate hundreds to thousands of genomic aberrations that distinguish them from normal (noncancerous) cells ( 10 ). Although only a minority of these genetic changes may be responsible for driving the tumor phenotype, the overall landscape of DNA alterations provides important information regarding tumor DNA damage exposure and repair capacity, and it can confer the tumor and microenvironment with unique properties that have the potential to be exploited therapeutically. TUMOR DNA REPAIR ALTERATIONS ARE BIOMARKERS AND THERAPEUTIC TARGETS Tumor DNA repair defi ciency has been a therapeutic target in oncology for more than a century, as evidenced by the widespread use of DNA-damaging chemotherapeutic agents and ionizing radiation. Several classes of DNA-damaging chemotherapy agents—including platinum-based agents, alkylating agents, and DNA intercalators—continue to comprise the backbone of many systemic therapy regimens, and radiation (alone or in combination with chemotherapy) is used in a variety of curative approaches. Although the mechanistic underpinnings of increased cancer cell sensitivity to DNA damage remain to be elucidated in many settings, the Cancer Research. on October 21, 2017. © 2017 American Association for cancerdiscovery.aacrjournals.org Downloaded from Published OnlineFirst June 19, 2017; DOI: 10.1158/2159-8290.CD-17-0226